Viking Therapeutics has contracted CDMO CordenPharma for a total of $150 million to make billions of clinical and commercial doses of its GLP-1/GIP receptor agonist for weight loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback